DrugPatentWatch Database Preview
Celgene Corp Company Profile
What is the competitive landscape for CELGENE CORP, and when can generic versions of CELGENE CORP drugs launch?
CELGENE CORP has two approved drugs.
There are sixteen US patents protecting CELGENE CORP drugs.
There are one hundred and thirty-three patent family members on CELGENE CORP drugs in thirty-one countries.
Summary for Celgene Corp
| International Patents: | 133 |
| US Patents: | 16 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Drug Master File Entries: | 4 |
| Patent Litigation for Celgene Corp: | See patent lawsuits for Celgene Corp |
| PTAB Cases with Celgene Corp as patent owner: | See PTAB cases with Celgene Corp as patent owner |
Drugs and US Patents for Celgene Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | RX | Yes | No | 6,020,358 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-003 | Mar 21, 2014 | RX | Yes | Yes | 7,659,302 | ➤ Sign Up | ➤ Sign Up | ||||
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | RX | Yes | No | 9,018,243 | ➤ Sign Up | ➤ Sign Up | ||||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | 10,093,654 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Celgene Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-002 | Mar 21, 2014 | 6,020,358 | ➤ Sign Up |
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | 6,020,358 | ➤ Sign Up |
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-003 | Mar 21, 2014 | 6,020,358 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for CELGENE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg, 20 mg and30 mg | ➤ Subscribe | 2018-03-22 |
International Patents for Celgene Corp Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Israel | 243833 | ➤ Sign Up |
| South Korea | 20110022736 | ➤ Sign Up |
| Spain | 2278467 | ➤ Sign Up |
| Singapore | 10201709187T | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
